GSPT1

VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Wednesday, February 7, 2024
Health, Technology, Research, Artificial Intelligence, Science, Pharmaceutical, Biotechnology, Jae, Northwestern University, CFO, Bristol Myers Squibb, GSPT1, Drug discovery, ADC, Citigroup, BBA, Sale, Media, Proximity, Korea University

VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Key Points: 
  • VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO).
  • Having led one of the largest deals in induced proximity history, she brings over 15 years of deal making experience to VantAI and its mission.
  • As COO/CFO of VantAI, Ms. Kim will oversee the company's operations, including finance, legal and corporate development functions.
  • "I am thrilled to join this incredible team at VantAI at this exciting time,” said Ms. Kim.

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 9, 2023
Research and development, American College, IND, MGD, PD, Public expenditure, Investigational New Drug, G&A, Inflammation, Treatment of lung cancer, MYC, R, GSPT1, Neoplasm, CDK2, Drug discovery, DSM-IV codes, Autoimmune disease, American College of Rheumatology, Roche, Cancer, Autoimmunity, Finance, Therapy, Patient, ACR, Administration, CIA, VAV1, Pharmaceutical industry, Vaccine, Cryptocurrency

"This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.

Key Points: 
  • "This has been a pivotal time for Monte Rosa as we announced both our first clinical data and our first major strategic collaboration,” said Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics.
  • Research and Development (R&D) Expenses: R&D expenses for the third quarter of 2023 were $28.3 million, compared to $21.3 million for the third quarter of 2022.
  • General and Administrative (G&A) Expenses: G&A expenses for the third quarter of 2023 were $8.7 million compared to $7.0 million for the third quarter of 2022.
  • Net Loss: Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.

Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Slate, Perella Weinberg Partners, Skadden, Arps, Slate, Meagher & Flom, Bristol Myers Squibb, Cancer, Acute myeloid leukemia, LLP, Patient, GSPT1, Pharmaceutical industry

Orum Therapeutics (“Orum”), a clinical-stage private biotechnology company pioneering Dual-Precision Targeted Protein Degradation (TPD² ™) and Targeted Protein Stabilization (TPS² ™), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has acquired Orum’s ORM-6151 program.

Key Points: 
  • Orum Therapeutics (“Orum”), a clinical-stage private biotechnology company pioneering Dual-Precision Targeted Protein Degradation (TPD² ™) and Targeted Protein Stabilization (TPS² ™), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has acquired Orum’s ORM-6151 program.
  • ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.
  • “We are excited that Bristol Myers Squibb has acquired our ORM-6151 program with proprietary GSPT1 degraders, first-in-class targeted protein degraders with the potential to make an impact for patients with cancer.”
    Under this transaction, Bristol Myers Squibb has acquired Orum’s ORM-6151 program for an upfront payment of $100 million, and Orum Therapeutics is eligible to receive milestone payments for a total deal value of $180 million.
  • Perella Weinberg Partners acted as financial advisor, and Sterne Kessler Goldstein & Fox, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to Orum Therapeutics.

Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors

Retrieved on: 
Tuesday, October 17, 2023
Cancer, Glomus tumor, Telephone, Hypocalcemia, Treatment of lung cancer, NSCLC, Trial of the century, First grade, Aes, SCLC, Cytokine release syndrome, Safety, Interim, Conference call, MD Anderson Cancer Center, Associate professor, Therapy, SD, DLT, University, Webcast, MGD, CRS, Lung, PD, Principal investigator, Neoplasm, Optimism, Prostate, Hypotension, Conference, Patient, MYC, Vaccine, Pharmaceutical industry, Medical imaging, GSPT1

BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including lung cancers and high-grade neuroendocrine cancer. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered by Monte Rosa Therapeutics. Cancers driven by MYC overexpression have been demonstrated to be dependent on GSPT1, creating a therapeutic opportunity.

Key Points: 
  • MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered by Monte Rosa Therapeutics.
  • Interim clinical data from the MRT-2359 study have demonstrated favorable tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in heavily pre-treated patients with lung cancers and high-grade neuroendocrine cancer.
  • Monte Rosa is continuing with dose level and schedule optimization in this ongoing study.
  • We continue to explore optimal doses and dosing schedules as we collect clinical data from this ongoing Phase 1/2 study," said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa Therapeutics.

Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, May 23, 2023
PK, PD, Autoimmunity, VAV1, Protein, Investigational New Drug, HIV disease progression rates, Patient, Biology, Therapy, IND, GSPT1, MGD, Safety, Disease, Vaccine, Pharmaceutical industry

The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.

Key Points: 
  • The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.
  • “MRT-6160 is a potent, orally bioavailable MGD designed to degrade VAV1, an important protein involved in the signaling pathways of T and B cells.
  • Our in vitro studies have shown that MRT-6160 selectively degrades VAV1 without detectable effects on other proteins.
  • “MRT-6160 is expected to be our second MGD to enter clinical trials, showcasing the continued productivity of our QuEEN™ platform.

Orum Therapeutics Unveils New Program at AACR 2023, Highlighting Cbl-b Inhibitor-PD-1 Conjugate, and Presents New Data Supporting Clinical Development of Two GSPT1 Programs

Retrieved on: 
Tuesday, April 18, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AACR, Perforin-1, PD, TP53, TGF, Neoplasm, ATF3, Cancer, Toxicity, SOC, Biomarker, Messenger, AML, Protein, Patient, Standard of care, Risk, T-cell surface glycoprotein CD3 epsilon chain, Growth, DDIT3, PD-1, FDA, Pembrolizumab, Therapy, GSPT1, Breast cancer, Vaccine, Palladium, Pharmaceutical industry, Regulatory T cell, CBL (gene)

The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The data were presented in three posters at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
  • “We are also excited to unveil at AACR our new TPS² platform, which has the potential to achieve the full promise of Cbl-b inhibitors through T cell-specific delivery.
  • Orum identified the depletion of GSPT1 as a target-proximal pharmacodynamic biomarker in ORM-5029 treated in vitro and in vivo samples.
  • PD responses correlate with degree and duration of response in an in vivo model treated with ORM-5029.

Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023

Retrieved on: 
Monday, April 17, 2023
Carcinoma, MYC, Index, AACR, PD, DLBCL, Survival, Disclosure, Clinical trial, Cancer, Lung cancer, American Association for Cancer Research, NSCLC, Treatment of lung cancer, SCLC, Patient, MTD, Growth, Trial of the century, AI, Therapy, Horizon, CDK9, GSPT1, MGD, Safety, Medical imaging, Pharmaceutical industry, Fine chemical, PDX

The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.

Key Points: 
  • The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL.
  • “Our extensive preclinical work on MRT-2359 forms a strong basis for our ongoing clinical trial by providing insight into the effects of GSPT1 degradation on the MYC pathway in cancer.
  • We look forward to reporting initial data from the Phase 1 arm of the trial later this year,” said Owen Wallace, Ph.D., Chief Scientific Officer of Monte Rosa.
  • The preclinical data were presented as follows:
    Title: New Drugs on the Horizon - Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers
    Session: New Drugs on the Horizon: Part 3
    Title: Development of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for the treatment of lung cancers with MYC-induced translational addiction

Captor Therapeutics Discloses Molecular Targets of Pipeline’s Lead Assets and Invites Stakeholders to Webcast

Retrieved on: 
Tuesday, March 28, 2023
Infection, CTX, Allergy, Hepatocellular carcinoma, WSE, Glomus tumor, Clinical trial, Cancer, NLRP3, CT-05, Breast, TPD, Research, Lung, Psoriasis, Inflammatory bowel disease, Malignancy, Patient, SALL4, Liver, GSPT1, HCC, Medical imaging, Vaccine

Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023.

Key Points: 
  • Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023.
  • It is therefore expected that selective degradation of NEK7 would also remove the NEK7 scaffolding function leading to potent inflammatory inhibition.
  • Pre-clinical studies have revealed the following benefits of CT-02:
    CT-05 targets the PKCӨ protein, a protein highly relevant in both autoimmune diseases and cancer.
  • It is therefore expected that degrading the PKCӨ protein would lead to an increased T cell suppressive function.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Lead, Finance, Public expenditure, SCLC, Chemistry, Food and Drug Administration, Horizon, NSCLC, GSPT1, Trial of the century, Lung cancer, PK, Fast Track, MGD, Cytokine, B-cell lymphoma, MTD, American Association for Cancer Research, Index, MYC, Research, AACR, Therapy, PD, Jennifer, Patient, Inflammation, FDA, VAV1, Cancer, Safety, Carcinoma, R, CDK2, Autoimmunity, Drug discovery, DLBCL, Treatment of lung cancer, Drug development, EORTC, Priority review, Process, Administration, Senior, Queen, Accelerated approval (FDA), Food, Research and development, Cryptocurrency, Pharmaceutical industry, G&A, IND

Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.

Key Points: 
  • Initiated patient dosing in October of its Phase 1/2 clinical trial evaluating MRT-2359 for the treatment of MYC-driven solid tumors, including lung cancer.
  • When activated, VAV1 relays a signal cascade that results in immune cell activation and the secretion of several pro-inflammatory cytokines.
  • Net Loss: Net loss for the fourth quarter of 2022 was $30.8 million compared to $23.4 million for the fourth quarter of 2021, and $108.5 million for the year ended December 31, 2022, compared to $74.0 million for the year ended December 31, 2021.
  • Cash Position and Financial Guidance: Cash, cash equivalents, restricted cash, and marketable securities as of December 31, 2022, were $268.1 million, compared to $351.4 million as of December 31, 2021.

Orum Therapeutics Announces Three Presentations at AACR 2023

Retrieved on: 
Tuesday, March 14, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, American Association for Cancer Research, AACR, Biomarker, Patient, AML, Acute myeloid leukemia, Breast cancer, TPD, IND, Toxicity, GSPT1, Pharmaceutical industry, CBL (gene)

Orum Therapeutics, Inc. (“Orum”), a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19 in Orlando.

Key Points: 
  • Orum Therapeutics, Inc. (“Orum”), a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place April 14-19 in Orlando.
  • ORM-5029 is a potential first-in-class targeted protein degrader therapy currently in a Phase 1 clinical trial for HER2-expressing breast cancer.
  • ORM-6151 is currently in the IND-enabling stage for CD33-positive hematologic malignancies, such as acute myeloid leukemia (AML).
  • This strategy is expected to limit systemic exposure of Cbl-b inhibitors and minimize c-Cbl inhibition that can lead to off-target toxicity.